Ms. Lynn Hanessian is Chief Science Strategist within Edelman’s Health practice, dedicated to science engagement and communication. She brings over 20 years of health and medical communications strategy leadership into every client engagement. Her ability to bring together industry, content and media expertise to galvanize ideas, strategies and programming for clients leads the industry.
Lynn’s recent client work has included Merck, Optimer Pharmaceuticals, Jazz Pharmaceuticals, University Hospitals, Otsuka, Rehabilitation Institute of Chicago, Millennium: The Takeda Oncology Company, and American Medical Association. Prior, Lynn served as chief executive officer of Zeno Group and general manager for the Edelman health team in Chicago.
A passionate patient advocate, Hanessian is board member and chair of the research, advocacy and public policy committee for the Asthma and Allergy Foundation of America and serves on the President’s Council of the Cancer Support Community.
Lynn earned an AB in economics from the University of Chicago.